| Literature DB >> 18339523 |
Dolunay Gülmez1, Neil Woodford, Marie-France I Palepou, Shazad Mushtaq, Gokhan Metan, Yusuf Yakupogullari, Sesin Kocagoz, Omrum Uzun, Gulsen Hascelik, David M Livermore.
Abstract
Treatment options are limited in infections caused by extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae, with carbapenems generally preferred. Disturbingly, however, carbapenem-resistant strains are emerging worldwide. Here we report two clinical isolates, one Escherichia coli and one Klebsiella pneumoniae, each with high-level carbapenem resistance (imipenem minimum inhibitory concentration of 32 microg/mL). They were isolated following imipenem therapy from two hospital patients who had received imipenem therapy in different regions of Turkey. Both isolates produced OXA-48-like carbapenemases, enzymes so far reported only from Turkey. Both isolates also had group 1 CTX-M-type ESBLs and had lost major outer membrane proteins. OXA-48-like carbapenemases appear to be scattered in Turkey and surveillance to determine their prevalence is warranted.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18339523 DOI: 10.1016/j.ijantimicag.2008.01.017
Source DB: PubMed Journal: Int J Antimicrob Agents ISSN: 0924-8579 Impact factor: 5.283